2019 Regular Session

Senate Bill 872

Requires pharmaceutical manufacturers to report to Department of Consumer and Business Services total amount of money spent on patient assistance programs, information on financial assistance provided to pharmacies, government agencies and advocacy organizations and total amount of financial incentives paid to each pharmacy benefit manager.

Did not become law. It stopped in the Senate on June 30, 2019. The 2019 session has ended.

What it does

The synopsis the Legislative Assembly published with the bill.

Requires pharmaceutical manufacturers to report to Department of Consumer and Business Services total cost of] amount of money spent on patient assistance programs, and] information on financial assistance provided to pharmacies, government agencies and advocacy organizations and total amount of financial incentives paid to each pharmacy benefit manager. Excludes proprietary information from disclosure on department's website.] Exempts from public disclosure information reported to department until department posts to website all information reported by manufacturer. Requires state-sponsored programs that use pharmacy benefit managers to use fee-only pharmacy benefit managers. Requires insurers to post specified information regarding formulary, tiers and costs for small employer and individual health benefit plans to insurer's website. Requires 60-day advance notice to department and to enrollees adversely affected by change in formulary. Requires insurer and allows pharmacy to notify insured that if cash] retail price for drug is less than insured's cost-share] out-of-pocket cost for drug using pharmacy benefit, insured may pay cash] retail price and expense must be counted] if requested by enrollee, insurer must count cost toward deductible or out-of-pocket maximum. Requires State Board of Pharmacy to prescribe by rule notice of enrollee's rights for distribution to pharmacy customers and to translate notice into multiple languages. Requires hospitals and other medical providers to disclose in patient billing information regarding mark-up on price of drug. Also requires billing to disclose price of drug charged to specified state agencies and insurers] report to Oregon Health Authority information regarding 50 most prescribed drugs and 50 most expensive drugs prescribed by provider. Requires specified state agencies to report to Legislative Assembly on high-cost drugs. Requires Oregon Health Authority to refer to Pharmacy and Therapeutics Committee any drug exceeding specified cost. Requires patient advocacy organization with budget] annual gross receipts exceeding $50,000 that has registered lobbyist in this state to report to Oregon Government Ethics Commission and Oregon Health Authority] specified information regarding funding received from participants in pharmaceutical supply chain. Requires pharmacy benefit managers to report to Department of Consumer and Business Services and plan sponsors specified information regarding rebates, reimbursements, fees and incentives paid for drugs by manufacturers, insurers and pharmacies. Requires insurers to include with rate filing certified statement regarding insurers' use of rebates. Requires drug advertisement to disclose wholesale price of drug.] Modifies responsibilities of Task Force on Fair Pricing of Prescription Drugs and requires report of findings, by September 15, 2020, to interim committees of Legislative Assembly related to health. Modifies reporting to department by insurers about costly drugs reimbursed by health benefit plans. Requires pharmaceutical manufacturers that register with State Board of Pharmacy to also register with department. Requires department to adopt registration fee based on reasonable cost to department to administer specified provisions.

Its course

February 28 to June 30, 2019, on one scale. In the top row each mark is a day something happened; taller marks are busier days.

Each committee stop sits inside its chamber.

Every action15 actions on 13 days

In the SenateFeb 28 to Jun 30 · stopped122 days

Waiting for a committeeFeb 28 to Mar 11 day

Health CareMar 1 to Mar 2928 days

Ways and MeansMar 29 to Jun 6 · moved on69 days

Human ServicesJun 6 to Jun 14 · moved on8 days

Capital ConstructionJun 14 to Jun 19 · moved on5 days

Ways and MeansJun 19 to Jun 212 days

Amendments

Each amendment offered, and what became of it.

Senate committee amendmentAdopted
Adopted Jun 21

Text

Each version as the Legislative Assembly printed it.

l9n doesn't hold this bill's text yet.

What happened

In l9n's words, one line for each step. Every action as the Legislative Assembly published it is below.

In the Senate Feb 28 – Jun 30

Feb 28Introduced
Mar 1Sent to Health Care
Mar 20Heard in Health Care
Mar 25Heard in Health Care
Mar 29Health Care recommended it, and that it go to Ways and Means
Sent to Ways and Means
Jun 6Sent to Human Services Subcommittee
Jun 10Heard in Human Services Subcommittee
Jun 14Sent to Capital Construction Subcommittee
Jun 19Heard in Capital Construction Subcommittee
Returned to Ways and Means
Jun 20Heard in Ways and Means
Jun 21Ways and Means recommended it as amended
Jun 29Read a second time
Jun 30Died when the session ended

All 15 actions, as published

Feb 28Introduction and first reading. Referred to President's desk.Senate
Mar 1Referred to Health Care.Senate
Mar 20Public Hearing held.Senate
Mar 25Work Session held.Senate
Mar 29Recommendation: Do Pass and be referred to Ways and Means.Senate
Mar 29Referred to Ways and Means by order of the President.Senate
Jun 6Assigned to Subcommittee On Human Services.Senate
Jun 10Public Hearing and Work Session held.Senate
Jun 14Assigned to Subcommittee On Capital Construction.Senate
Jun 19Work Session held.Senate
Jun 19Returned to Full Committee.Senate
Jun 20Work Session held.Senate
Jun 21Recommendation: Do pass with amendments. (Printed A-Eng.)Senate
Jun 29Second reading.Senate
Jun 30At Desk upon adjournment.Senate